DBV TECH SA-ADR (NASDAQ:DBVT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday. The firm currently has a $38.00 target price on the stock. Zacks Investment Research’s price target would indicate a potential upside of 13.74% from the stock’s current price.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
DBVT has been the topic of several other research reports. JMP Securities began coverage on shares of DBV TECH SA-ADR in a report on Monday, September 26th. They issued an “outperform” rating and a $47.00 price target on the stock. Jefferies Group set a $47.00 price target on shares of DBV TECH SA-ADR and gave the stock a “buy” rating in a report on Monday, October 24th. Six investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $46.50.
DBV TECH SA-ADR (NASDAQ:DBVT) traded down 1.76% during midday trading on Thursday, hitting $33.41. 82,927 shares of the company traded hands. DBV TECH SA-ADR has a 12-month low of $22.55 and a 12-month high of $37.98. The stock’s market cap is $1.54 billion. The stock has a 50 day moving average of $35.47 and a 200 day moving average of $35.30.
A number of hedge funds and other institutional investors have recently made changes to their positions in DBVT. Price T Rowe Associates Inc. MD bought a new position in shares of DBV TECH SA-ADR during the third quarter valued at about $6,114,000. Baker BROS. Advisors LP bought a new position in shares of DBV TECH SA-ADR during the third quarter valued at about $200,162,000. OLD Mission Capital LLC bought a new position in shares of DBV TECH SA-ADR during the third quarter valued at about $2,207,000. Great Point Partners LLC bought a new position in shares of DBV TECH SA-ADR during the third quarter valued at about $4,776,000. Finally, Sphera Funds Management LTD. raised its position in shares of DBV TECH SA-ADR by 30.4% in the third quarter. Sphera Funds Management LTD. now owns 79,058 shares of the company’s stock valued at $2,872,000 after buying an additional 18,447 shares during the period. Institutional investors own 49.02% of the company’s stock.
DBV TECH SA-ADR Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Get a free copy of the Zacks research report on DBV TECH SA-ADR (DBVT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com